BRAF and MEK inhibitor therapy eliminates nestin expressing melanoma cells in human tumors Experiment 5 (Additional Therapy Naive Patients All Cells)

To provide single-cell mass cytometry data of melanoma treatment response after dabrafenib and trametinib therapy. This panel dissects melanoma cancer cell heterogeneity to identify subset phenotypes that escape therapy.
Conclusion:
This data was utilized to identify CD45 low/negative melanoma cells. We observed a decrease in neural crest biomarker nestin positive melanoma subsets after targeted therapy.
Notes:
These events are intact cells pre-gated with iridium intercalator. This analysis pairs with Figure 4 in the manuscript titled "BRAF and MEK inhibitor therapy eliminates nestin expressing melanoma cells in human tumors".Patients received gadolinium contrast agent before each sample was acquired. Channels 155, 156, 157, 158, and 160 may have gadolinium contrast agent contamination. These events are intact cells pre-gated with iridium intercalator. Each patient was run the same day to minimize instrument variation.